- Home
- FWRG vs LXRX Comparison
FWRG vs LXRX Comparison
Compare FWRG & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FWRG | LXRX |
|---|---|---|
| Founded | 1983 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 745.9M | 703.3M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | FWRG | LXRX |
|---|---|---|
| Price | $12.74 | $2.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 2 |
| Target Price | ★ $20.46 | $4.15 |
| AVG Volume (30 Days) | 1.1M | ★ 2.3M |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.33 | ★ 77.78 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,222,501,000.00 | $49,803,000.00 |
| Revenue This Year | $15.58 | N/A |
| Revenue Next Year | $12.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 20.34 | ★ 60.24 |
| 52 Week Low | $9.97 | $0.80 |
| 52 Week High | $19.53 | $2.53 |
Technical Indicators
Market Signals| Indicator | FWRG | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.89 | 74.41 |
| Support Level | $10.22 | $1.11 |
| Resistance Level | $13.82 | $2.53 |
| Average True Range (ATR) | 0.67 | 0.13 |
| MACD | 0.16 | 0.05 |
| Stochastic Oscillator | 96.65 | 97.10 |
Price Performance
Historical ComparisonAbout FWRG First Watch Restaurant Group Inc.
First Watch Restaurant Group Inc is a daytime restaurant concept serving made-to-order breakfast, brunch, and lunch using fresh ingredients. The company generates revenues from Restaurant sales and Franchise revenues. It generates maximum revenue from Restaurant sales.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.